Venrock Healthcare Capital Partners III, L.P. sold KALV

March 25, 2026 · Form 4 insider transaction

Venrock Healthcare Capital Partners III, L.P. sold 174,485 shares of KalVista Pharmaceuticals Inc at $16.95 per share, a transaction worth $2.96M. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Disposed (sell-side)
Shares
174,485
Price
$16.95
Total value
$2.96M
Role10% owner
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateMarch 25, 2026
Filing dateMarch 27, 2026
Shares owned after5,129,500
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $16.51 to $17.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.; Consists of (i) 1,105,126 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 110,550 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,913,824 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").; VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.

View the original Form 4 on SEC EDGAR